C
Colleen F. Kelley
Researcher at Emory University
Publications - 97
Citations - 4326
Colleen F. Kelley is an academic researcher from Emory University. The author has contributed to research in topics: Men who have sex with men & Medicine. The author has an hindex of 26, co-authored 85 publications receiving 3270 citations. Previous affiliations of Colleen F. Kelley include University of California, San Francisco & Harvard University.
Papers
More filters
Journal ArticleDOI
The Transgenic RNAi Project at Harvard Medical School: Resources and Validation
Lizabeth A. Perkins,Laura Holderbaum,Rong Tao,Yanhui Hu,Richelle Sopko,Kim McCall,Donghui Yang-Zhou,Ian Flockhart,Richard Binari,Richard Binari,Hye Seok Shim,Audrey Miller,Amy Housden,Marianna Foos,Sakara Randkelv,Colleen F. Kelley,Pema Namgyal,Christians Villalta,Christians Villalta,Lu Ping Liu,Lu Ping Liu,Xia Jiang,Qiao Huan-Huan,Xia Wang,Asao Fujiyama,Atsushi Toyoda,Kathleen Ayers,Allison Blum,Allison Blum,Benjamin Czech,Ralph A. Neumüller,Dong Yan,Amanda Cavallaro,Karen L. Hibbard,Donald Hall,Lynn Cooley,Gregory J. Hannon,Ruth Lehmann,Ruth Lehmann,Annette L. Parks,Stephanie E. Mohr,Ryu Ueda,Shu Kondo,Shu Kondo,Jian-Quan Ni,Jian-Quan Ni,Norbert Perrimon,Norbert Perrimon +47 more
TL;DR: The various tools developed and the status of the TRiP collection, which is currently composed of 11,491 lines and covering 71% of Drosophila genes, are described.
Journal ArticleDOI
Incomplete Peripheral CD4+ Cell Count Restoration in HIV-Infected Patients Receiving Long-Term Antiretroviral Treatment
Colleen F. Kelley,Christina M. R. Kitchen,Peter W. Hunt,Benigno Rodriguez,Frederick Hecht,Mari M. Kitahata,Heide M. Crane,James H. Willig,Michael J. Mugavero,Michael S. Saag,Jeffrey N. Martin,Steven G. Deeks +11 more
TL;DR: A substantial proportion of patients who delay therapy until their CD 4(+) cell count decreases to <200 cells/mm(3) do not achieve a normal CD4(+)cell count, even after a decade of otherwise effective antiretroviral therapy.
Journal ArticleDOI
The safety, immunogenicity, and acceptability of inactivated influenza vaccine delivered by microneedle patch (TIV-MNP 2015): a randomised, partly blinded, placebo-controlled, phase 1 trial
Nadine Rouphael,Michele Paine,Regina Mosley,Sebastien Henry,Devin V. McAllister,Haripriya Kalluri,Winston P. Pewin,Paula M. Frew,Tianwei Yu,Natalie J. Thornburg,Sarah Kabbani,Lilin Lai,Elena V. Vassilieva,Ioanna Skountzou,Richard W. Compans,Mark J. Mulligan,Mark R. Prausnitz,Allison Beck,Srilatha Edupuganti,Sheila Heeke,Colleen F. Kelley,Wendy Nesheim +21 more
TL;DR: Safety, immunogenicity, and acceptability of the first-in-man study on single, dissolvable microneedle patch vaccination against influenza are described and secondary safety outcomes are new-onset chronic illnesses within 180 days and unsolicited adverse events within 28 days, all analysed by intention to treat.
Journal ArticleDOI
Applying a PrEP Continuum of Care for Men Who Have Sex With Men in Atlanta, Georgia.
Colleen F. Kelley,Erin M. Kahle,Aaron J Siegler,Travis Sanchez,Carlos del Rio,Patrick S. Sullivan,Eli S. Rosenberg +6 more
TL;DR: This work evaluated the PrEP care continuum on an Atlanta cohort of MSM and projected how many MSM might achieve protection from HIV with PrEP, and proposed a simplified framework, similar to the HIV care continuum, to achieve protection.
Journal ArticleDOI
Safety, tolerability, and immunogenicity of two Zika virus DNA vaccine candidates in healthy adults: randomised, open-label, phase 1 clinical trials
Martin R. Gaudinski,Katherine V. Houser,Kaitlyn M. Morabito,Zonghui Hu,Galina Yamshchikov,Ro Shauna S Rothwell,Nina M. Berkowitz,Floreliz Mendoza,Jamie G. Saunders,Laura Novik,Cynthia S. Hendel,LaSonji A. Holman,Ingelise J. Gordon,Josephine H. Cox,Srilatha Edupuganti,Monica A. McArthur,Nadine Rouphael,Kirsten E. Lyke,Ginny E. Cummings,Sandra Sitar,Robert T. Bailer,Bryant M. Foreman,Katherine E. Burgomaster,Rebecca S. Pelc,David N. Gordon,Christina R. DeMaso,Kimberly A. Dowd,Carolyn M. Laurencot,Richard M. Schwartz,John R. Mascola,Barney S. Graham,Theodore C. Pierson,Julie E. Ledgerwood,Grace L. Chen,Sarah H. Plummer,Pamela Costner,Kathryn Zephir,Joseph P. Casazza,Abidemi Ola,Milalynn Victorino,Carol Levinson,William Whalen,Xiaolin Wang,Jennifer Cunningham,Olga Vasilenko,Maria Burgos Florez,Somia P. Hickman,Iris Pittman,Lam Le,Brenda Larkin,Charla A. Andrews,Preeti Apte,Renunda Hicks,Cora Trelles Cartagena,Pernell Williams,Catina R. Boyd,Michelle Conan-Cibotti,Judy Stein,Florence Kaltovich,Hope DeCederfelt,Stacey McAdams,Phyllis Renehan,Wilbur Chen,Nancy Greenberg,Nancy Wymer,Linda Wadsworth,Melissa Billington,Toni Robinson,Colleen Boyce,Faith Pa'ahana Brown,Lisa Chrisley,Alyson Kwon,Prashant Patel,Panagoita Kominou,Brenda Dorsey,Staci Eddington,Shinyi Telscher,Myoughee Lee,Regina Mosely,April Ross,Geoffrey Ford,Briyana Domjahn,Jianguo Xu,Allison Beck,Rebecca Fineman,Shiela Heeke,Jean Winter,Shashi Nagar,Colleen F. Kelley,Mark J. Mulligan +89 more
TL;DR: Both DNA vaccines expressing premembrane and envelope Zika virus structural proteins were safe and well tolerated and followed up volunteers for 24 months for safety and immunogenicity, respectively.